Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2017, 7878605

Prognostic Factors for Immune Thrombocytopenia Outcome in Greek Children: A Retrospective Single-Centered Analysis


Prognostic Factors for Immune Thrombocytopenia Outcome in Greek Children: A Retrospective Single-Centered Analysis

Alexandros Makis et al. Adv Hematol.


Immune thrombocytopenia (ITP) in children has a varied course and according to duration is distinguished as newly diagnosed (<3 months), persistent (3-12), and chronic (>12) types. Several studies have evaluated the prognostic factors for the progression of the disease, but similar works have yet to be performed in Greece. We aimed to identify prognostic markers for the three forms of the disease in 57 Greek children during a 13-year period. Information regarding age, gender, preceding infection, bleeding type, duration of symptoms and platelets at diagnosis, treatment, disease course, and immunological markers was recorded. 39 children had newly diagnosed, 4 persistent, and 14 chronic disease. Chronic ITP children were more likely to be of age > 10 years (p = 0.015) and have gradual initiation of the disease (p = 0.001), platelets > 10 × 109/L (p = 0.01), and impaired immunological markers (p < 0.003) compared to newly diagnosed/persistent groups. Recent history of infection was found mainly in the newly diagnosed/persistent group (p = 0.013). None of the children exhibited severe spontaneous bleeding. Conclusion. Even though ITP in children usually has a self-limited course, with rare serious bleeding complications, the chronic form of the disease is characterized by different predictive parameters, which can be used in clinical practice.


Figure 1
Figure 1
(a) Number of children with newly diagnosed/persistent (ND + P) and chronic (C) ITP, (b) percentage of children < 10 years or >10 years of age, (c) percentage of children with a history of recent infection or not, and (d) percentage of children with platelets less or more than 10 × 109/L, at diagnosis.
Figure 2
Figure 2
(a) Percentage of children with newly diagnosed/persistent (ND + P) and chronic (C) ITP with mucosal bleeding at diagnosis or not, (b) percentage of children with abrupt (<2 weeks) or gradual (>2 weeks) symptomatology before diagnosis, (c) percentage of children with normal or impaired immunological markers, and (d) percentage of children who received or did not receive treatment with intravenous immunoglobulin and/or corticosteroids.

Similar articles

See all similar articles

Cited by 1 article


    1. Abadi U., Dolberg O. Y., Ellis M. H. Immune thrombocytopenia: recent progress in pathophysiology and treatment. Clinical and Applied Thrombosis/Hemostasis. 2015;21(5):397–404. doi: 10.1177/1076029614526639. - DOI - PubMed
    1. Fogarty P. F., Segal J. B. The epidemiology of immune thrombocytopenic purpura. Current Opinion in Hematology. 2007;14(5):515–519. doi: 10.1097/MOH.0b013e3282ab98c7. - DOI - PubMed
    1. Arnold D. M. Bleeding complications in immune thrombocytopenia. International Journal of Hematology. 2015;2015(1):237–242. doi: 10.1182/asheducation-2015.1.237. - DOI - PubMed
    1. Rodeghiero F., Stasi R., Gernsheimer T., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi: 10.1182/blood-2008-07-162503. - DOI - PubMed
    1. Provan D., Stasi R., Newland A. C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–186. doi: 10.1182/blood-2009-06-225565. - DOI - PubMed

LinkOut - more resources